Transcat Names John Harms Vice President, Compliance

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Transcat Names John Harms Vice President, Compliance Services

ROCHESTER, N.Y., Oct. 2, 2013 (GLOBE NEWSWIRE) -- Transcat, Inc. (Nasdaq: TRNS ) (Transcat or the "Company"), a leading provider of accredited calibration, repair, inspection and compliance services and distributor of professional grade, handheld test, measurement and control instrumentation, announced that John Harms joined the Company as Vice President of Compliance Services.

Within this role, Mr. Harms will lead Transcat's initiatives to further develop relationships in the Analytical and Validation business. Mr. Harms has several years of industry related experience and has demonstrated success in establishing and growing account relationships with major FDA regulated, life science and medical devices manufacturing companies. 

Lee D. Rudow, President and CEO of Transcat commented, "The addition of John further strengthens our already strong leadership team. His blended background of business development and operational leadership creates unique value for Transcat and is a perfect fit for the recently acquired Validation and Analytical Qualification services.  His track record for driving growth and profitability will help foster our ambitious expectations for this business." 

Prior to joining Transcat, Mr. Harms worked 12 years for Tektronix/Sypris Technologies, where he held leadership roles in both strategic business development and service operations.  His past experience also includes management roles for Telogy and Instrument Repair Labs, with oversight and P&L responsibility for multiple business units.

ABOUT TRANSCAT

Transcat, Inc. is a leading provider of accredited calibration, repair, inspection and compliance services including analytical instrument qualifications, equipment and process validation. Targeted industries include life science, biotechnology, medical device, pharmaceutical and other FDA-regulated industries, industrial manufacturing, energy and utilities, chemical manufacturing and other industries. Throughout its 18 strategically located centers of excellence in the United States, Canada and Puerto Rico, Transcat delivers precise services with reliable turn-around times. The breadth and depth of measurement parameters addressed by Transcat's ISO/IEC 17025 scopes of accreditation are believed to be among the best in the industry.

In addition, Transcat operates as a leading distributor of professional grade handheld test, measurement and control instrumentation. Through its distribution products segment, Transcat markets and distributes premier and propriety brand instruments to nearly 15,000 customers. The Company offers access to more than 25,000 test, measurement and control products.

Transcat's growth strategy is to expand its service and distribution platform comprised of a balanced suite of test products and analytical, calibration, compliance, and validation services. The goal is to deliver specialized technical services with a quality assurance approach, which maximizes document accuracy and on-time job delivery. Transcat answers the call with cGMP, GLP, and GXP compliant services. Transcat can provide life science companies with a reliable alternative service and product solution to the OEMs and to the "generalist" service providers who cannot meet the client's specialized needs.

More information about Transcat can be found on its website at: transcat.com .

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as "expects," "estimates," "projects," "anticipates," "believes," "could," and other similar words. All statements addressing operating performance, events, or developments that Transcat, Inc. expects or anticipates will occur in the future, including but not limited to statements relating to anticipated revenue, profit margins, sales operations, its strategy to build its sales representative channel, customer preferences and changes in market conditions in the industries in which Transcat operates are forward-looking statements. Because they are forward-looking, they should be evaluated in light of important risk factors and uncertainties. These risk factors and uncertainties are more fully described in Transcat's Annual and Quarterly Reports filed with the Securities and Exchange Commission, including under the heading entitled "Risk Factors." Should one or more of these risks or uncertainties materialize, or should any of the Company's underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on the Company's forward-looking statements. Except as required by law, the Company disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release.

John J. Zimmer, Chief Financial Officer Phone: (585) 352-7777 Email: -or- Deborah K. Pawlowski, Investor Relations Phone: (716) 843-3908 Email:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 34

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 26

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 19

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 21

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 28

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 26

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Crypto Developments: Circle's Blockchain, Ethereum Bets, and More

Updated Category News Views 251

The Current Landscape of Cryptocurrency The last week in the world of cryptocurrency and finance has been nothing less than exhilarating. With significant developments, including the launch of a new blockchain by Circle Internet Group Inc. and major investments in Ethereum, there is plenty to discuss. Let’s explore the most noteworthy stories that are shaping the crypto...

Continue Reading
ezPaycheck 2025 Payroll Software: Cost-Effective Compliance Solution

Updated Category News Views 132

ezPaycheck 2025: The Efficient Payroll Solution The new ezPaycheck 2025 payroll software is now available, offering businesses an excellent in-house solution for payroll processing that is both compliant and economical. This updated version comes with essential features designed to make payroll management easier than ever. Priced at just $169 for a single installation,...

Continue Reading
Investors of Applied Therapeutics, Inc. Should Take Action Now

Updated Category News Views 188

Understanding the Securities Fraud Allegations Against Applied Therapeutics Applied Therapeutics, Inc. (APLT) has found itself at the heart of a securities fraud class action lawsuit. This legal proceeding has been announced by The Law Offices of Frank R. Cruz as they represent investors who acquired shares during a significant time frame. The legal challenge highlights...

Continue Reading
Ardagh Metal Packaging Reports Positive Year-End 2024 Results

Updated Category News Views 148

Ardagh Metal Packaging's Year-End 2024 Results Ardagh Metal Packaging S.A. (NYSE: AMBP) recently reported their impressive results for the full year and fourth quarter of 2024. The company's performance is a reflection of strategic growth and resilience in a challenging market environment. Quarterly and Annual Performance Overview For the fourth quarter of 2024, Ardagh...

Continue Reading
Empowering Voices: The Call to Protect Our Children

Updated Category News Views 243

Making a Stand Against Child Trafficking In a heartfelt initiative, ThinkCareBelieve has announced a powerful call to action aimed at ensuring the safety and protection of children across the nation. This initiative addresses the urgent concern of child trafficking and the plight of missing children, many of whom have been smuggled through borders and placed in unsafe...

Continue Reading